Association between coronary artery calcifications and pre-bronchodilator airflow limitation among individuals with LDCT-detected emphysema: Findings from a lung cancer screening program

Le résumé fourni par la source

Introduction: Coronary artery calcifications (CAC) and emphysema are common findings detected during low-dose computed tomography (LDCT) lung cancer screening. This study investigated the association between CAC and pulmonary function parameters among individuals with CT-detected emphysema. Materials and Methods: This cross-sectional study included 323 participants with radiographically detected emphysema identified through a lung cancer screening program. All participants underwent pre-bronchodilator spirometry. We evaluated associations among CAC, pre-bronchodilator airflow limitation, and pulmonary function parameters. We used multivariable logistic regression to identify factors independently associated with CAC. Results: Coronary artery calcifications were present in 216 participants (66.9%). Participants with CAC were significantly older than those without CAC (68.2 ± 6.7 vs. 61.1 ± 7.1 years, p < 0.001) and were more frequently male (59.3% vs. 32.7%, p < 0.001). Pre-bronchodilator airflow limitation was significantly more common among participants with CAC (50.0% vs. 35.5%; p = 0.014). No significant differences were observed in FEV1 or FVC values. In multivariable logistic regression analysis, age and male sex were independently associated with CAC, whereas pre-bronchodilator airflow limitation was not independently associated with CAC after adjustment. Conclusion: Among individuals with CT-detected emphysema, coronary artery calcifications were associated with a higher prevalence of pre-bronchodilator airflow limitation. However, age and male sex were the strongest independent predictors of CAC, suggesting that shared demographic and cardiovascular risk factors may account for much of the observed overlap between pulmonary and cardiovascular abnormalities. These findings support the value of integrated cardiopulmonary assessment within lung cancer screening programs.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.